G. Cervantes

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

David Miles, Shailendra Verma, Chris Twelves, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.

B. Erikstein, S. Verma, D. Miles, 2001 .

Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC)

D. Miles, L. Mauriac, J. O’Shaughnessy, 2001 .

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

D. Miles, L. Mauriac, J. O’Shaughnessy, 2004, Clinical Breast Cancer.

B3-06: Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)

A. Ardizzoni, M. Lichinitser, U. Yilmaz, 2007 .

Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial.

G. Cervantes, P. Cortes, L. Pérez, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of Neo-Adjuvant chemotherapy (CT) with Ifosfamide (I), Mesna and Cisplatinum (C) in stage IIA-IIIB cervical cancer

A. Erazo, G. Cervantes, B. Ortega, 1994 .

Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP.

A. Erazo, C. Corrado, G. Cervantes, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.